Anthropic bought Mithril Medicine, a one-employee drug startup that used Claude to run its lab work. It hints at how small teams may work with AI.
Anthropic, the maker of the AI model Claude, said Oct. 27 that it bought Mithril Medicine, a startup working on treatments for two rare forms of muscular dystrophy. The company had just one full-time employee, founder Cody Tranbarger. He used Claude to run contracts, logistics and experiments across 11 outside labs.
Tranbarger also handed other parts of the business to the AI. Under his lead, Mithril took one drug candidate from idea to promising results in mice in under 18 months. He has now joined Anthropic and plans to start several more programs.
Anthropic says running real drug programs shows it where Claude holds up and where it fails. The programs also give it case studies to share with other biotech firms, and possibly medicines of its own if the candidates work.
Mithril's lead antibody has been tested only in mice. Anthropic says the work is mostly preclinical, meaning it comes before any human testing. The company says a drug could be ready for human trials as soon as late 2028. It plans to extend Claude into clinical trials as the programs advance.
OpenAI agreed Oct. 20 to buy Orchestra Bio, a startup whose AI agents track drug program timelines. If a manufacturing batch fails and threatens a trial start, the agents work out which dates are affected and lay out options. Scientists and program leaders still decide what to do.
The first clear savings are in paperwork. Biotech firm Enveda built a Claude-based tool to review manufacturing records that a drugmaker files before a trial. It caught all 11 issues human reviewers found across 1,061 pages and flagged seven they missed. Review time fell from almost 26 hours to just under three.
Moving a drug from target discovery to approval takes 10 to 15 years, PYMNTS reported in April. Healthcare firms are planning for AI help. In a PYMNTS Intelligence survey of 60 senior technology executives at large U.S. companies, 84% of healthcare firms expected to spend more on AI over the next 12 months, and none expected to spend less.
Anthropic's stock market filing, dated Oct. 26, lists healthcare and life sciences first among the new markets it wants to enter.
One person plus AI ran a drug startup to mouse results, but nothing has been tested in people yet, so the real proof is still years away.
A former Nvidia product manager has started Udu Technologies to let African startups and institutions rent AI computing power instead of buying it.
Read more: Ex-Nvidia engineer starts company to bring AI computing power to AfricaEA has re-released 25 classic PC games at a discount until November 19, and Bethesda has finally given The Elder Scrolls VI a subtitle: Sentinel.
Read more: EA brings 25 classic PC games back, and Elder Scrolls VI gets a nameOpenAI released a ChatGPT for analysts and bankers that shows where each number came from, a feature that could matter well beyond finance.
Read more: OpenAI launches a ChatGPT built for Wall Street analysts
